Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DICLOFENAC SODIUM & MISOPROSTOL

All products: general benefit

Other products in the same Health Canada class (M01A, M01AB) — coverage varies; not interchangeable

  • Diclofenac (Voltaren): general benefit, Not a benefit
  • Indomethacin (Indocid): general benefit, Not a benefit
  • Sulindac (Clinoril): general benefit, Not a benefit
  • Diclofenac (Voltaren Rapide): not a benefit
  • Ketorolac tromethamine (Toradol): not a benefit
  • Flurbiprofen (Ansaid): general benefit, Not a benefit

12 more in the class list below

Arthrotec 50 · DIN 01917056 · 50mg & 200mcg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Arthrotec (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Arthrotec 50 · DIN 01917056 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2005-11-21 · brand ARTHROTEC 50 · ATC M01AB55 DICLOFENAC, COMBINATIONS · form Tablet (delayed-release) · route Oral · ingredients DICLOFENAC SODIUM 50 MG, MISOPROSTOL 200 MCG · company Accudial pharmaceutical inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3149 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13636 · Verify on the e-Formulary ↗ (DIN 01917056)

Source record
DIN 01917056: Arthrotec 50 Raw flags: sec3=Y Item: 280804049; group id 380; item number 0907; lccId None; manufacturer id PFI Source form: Tab; strength: 50mg & 200mcg Recorded listing: General benefit Source prices (unrounded): $0.7788; ministry $0.3149 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01917056 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13636 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Gd-Diclofenac/Misoprostol 50 · DIN 02341689 · $0.3149 PMS-Diclofenac-Misoprostol · DIN 02413469 · $0.3149
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab

DICLOFENAC POTASSIUM

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg · Tab

KETOROLAC TROMETHAMINE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (8) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

PIROXICAM

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 10mg, 20mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the signs and symptoms of rheumatoid arthritis and osteoarthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. NABUMETONE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS NABUMETONE (Nabumetone tablets) is indicated for:  Acute and chronic relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. PM: https://pdf.hres.ca/dpd_pm/00070052.PDF; date MAR 24, 2023; DIN 02238639; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ARTHROTEC (diclofenac sodium and misoprostol) is indicated for: • Acute and chronic use in the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Throughout this document, the term NSAIDs refers to both non-selective NSAIDs and selective COX-2 inhibitor NSAIDs, unless otherwise indicated. Diclofenac, particularly at higher doses, is associated with an increased risk of serious cardiovascular related adverse events that is comparable to COX-2 inhibitors and high dose ibuprofen. For patients with pre-existing risk factors for cardiovascular disease (including ischemic heart disease, cerebrovascular disease and/or congestive heart failure NYHA II-IV) other management strategies that do not include NSAlDs, particularly COX-2 inhibitors, ibuprofen and diclofenac, should be considered first (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS). For patients with increased risk of developing GI adverse events other management strategies that do not include NSAlDs should be considered first (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS). Use of ARTHROTEC should be limited to the lowest effective dose for the shortest possi… https://pdf.hres.ca/dpd_pm/00074559.PDF PM date: JAN 15, 1993 Source product: ARTHROTEC 50; DIN 01917056; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.